Impact of body composition on survival and morbidity after liver resection in hepatocellular carcinoma patients
- PMID: 30115516
- DOI: 10.1016/j.hbpd.2018.07.008
Impact of body composition on survival and morbidity after liver resection in hepatocellular carcinoma patients
Abstract
Background: Hepatocellular carcinoma is the most common innate liver tumor. Due to improved surgical techniques, even extended resections are feasible, and more patients can be treated with curative intent. As the liver is the central metabolic organ, preoperative metabolic assessment is crucial for risk stratification. Sarcopenia, obesity and sarcopenic obesity characterize body composition and metabolic status. Here we present the impact of body composition on survival after liver resection in patients with hepatocellular carcinoma.
Methods: A retrospective database analysis of 70 patients who were assigned for liver resection due to hepatocellular carcinoma was conducted. For assessment of sarcopenia and obesity, skeletal muscle surface area was measured at lumbar vertebra 3 level (L3) in preoperative four-phase contrast enhanced abdominal CT scans, and L3 muscle index and body fat percentage were calculated.
Results: Univariate analysis comparing the survival curves using the score test demonstrated superior postoperative overall survival for sarcopenic (P = 0.035) and sarcopenic obese (P = 0.048) patients as well as a trend favoring obese (P = 0.130) subjects. Whereas multivariate analysis could not identify significant difference in postoperative survival regarding sarcopenia, obesity or sarcopenic obesity. Only large tumor size, multifocal disease and male gender were risk factors for long-term survival.
Conclusions: Sarcopenia, obesity and sarcopenic obesity are indeed no risk factors for poor postoperative survival in this study. Our data do not support the evaluation of sarcopenia, obesity and sarcopenic obesity before liver resection in hepatocellular carcinoma patients.
Keywords: Hepatocellular carcinoma; Liver resection; Obesity; Sarcopenia; Sarcopenic obesity.
Copyright © 2018. Published by Elsevier B.V.
Similar articles
-
Impact of Sarcopenic Obesity on Outcomes in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma.Ann Surg. 2019 May;269(5):924-931. doi: 10.1097/SLA.0000000000002555. Ann Surg. 2019. PMID: 29064889
-
Impact of Sarcopenia as a Prognostic Factor on Reductive Hepatectomy for Advanced Hepatocellular Carcinoma.Anticancer Res. 2021 Nov;41(11):5775-5783. doi: 10.21873/anticanres.15394. Anticancer Res. 2021. PMID: 34732451
-
Effect of Sarcopenia on the Prognosis of Clinical Outcomes in Patients With Hepatocellular Carcinoma After Hepatic Resection.Am Surg. 2024 Jun;90(6):1447-1455. doi: 10.1177/00031348241241713. Epub 2024 Mar 22. Am Surg. 2024. PMID: 38516765
-
Sarcopenia and sarcopenic obesity.Korean J Intern Med. 2016 Nov;31(6):1054-1060. doi: 10.3904/kjim.2016.193. Epub 2016 Nov 1. Korean J Intern Med. 2016. PMID: 27809450 Free PMC article. Review.
-
Resection strategies for hepatocellular carcinoma.Semin Liver Dis. 2013 Aug;33(3):273-81. doi: 10.1055/s-0033-1351782. Epub 2013 Aug 13. Semin Liver Dis. 2013. PMID: 23943107 Review.
Cited by
-
Impact of sarcopenia and sarcopenic obesity on survival in patients with primary liver cancer: a systematic review and meta-analysis.Front Nutr. 2023 Oct 19;10:1233973. doi: 10.3389/fnut.2023.1233973. eCollection 2023. Front Nutr. 2023. PMID: 37927508 Free PMC article.
-
Understanding the development of sarcopenic obesity.Expert Rev Endocrinol Metab. 2023 Sep-Nov;18(6):469-488. doi: 10.1080/17446651.2023.2267672. Epub 2023 Nov 28. Expert Rev Endocrinol Metab. 2023. PMID: 37840295 Free PMC article. Review.
-
Association between sarcopenia and clinical outcomes in patients with hepatocellular carcinoma: an updated meta-analysis.Sci Rep. 2023 Jan 17;13(1):934. doi: 10.1038/s41598-022-27238-z. Sci Rep. 2023. PMID: 36650190 Free PMC article.
-
Combination of psoas muscle mass index and neutrophil/lymphocyte ratio as a prognostic predictor for patients undergoing nonsurgical hepatocellular carcinoma therapy.JGH Open. 2021 Nov 19;5(12):1335-1343. doi: 10.1002/jgh3.12676. eCollection 2021 Dec. JGH Open. 2021. PMID: 34950776 Free PMC article.
-
Macrophages protect against loss of adipose tissue during cancer cachexia.J Cachexia Sarcopenia Muscle. 2019 Oct;10(5):1128-1142. doi: 10.1002/jcsm.12450. Epub 2019 Jul 18. J Cachexia Sarcopenia Muscle. 2019. PMID: 31318182 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials